Skip Navigation

Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated with favipiravir (T-705), Sierra Leone, 2014

  1. Jia-Fu Jiang4,#
  1. 1The No. 307 Hospital Beijing, China
  2. 2The No. 302 Hospital, Beijing, China
  3. 3Sierra Leone Ministry of Health and Sanitation
  4. 4Beijing Institute of Microbiology and Epidemiology, Beijing, China
  5. 5Sierra Leone-China Friendship Hospital, Freetown, Sierra Leone
  6. 6The Kingharman Road Hospital in Freetown, Sierra Leone
  7. 7Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun, China
  8. 8Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  9. 9Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention
  10. 10Chinese Center for Disease Control and Prevention, Beijing, China
  1. Corresponding author: Dr. Jia-Fu Jiang, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, No. 20, Dong-Da Street, Fengtai District, Beijing 100071, China, jiangjf2008{at}
  1. * C. B., J. M., D. K., and Y. S. contributed equally to this work;

  2. # H. W., B. K., G. F. G. and J. J. contributed equally to this work;


Background. During 2014–2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. No approved antiviral drugs are available for Ebola treatment currently.

Methods. A retrospective clinical case series was performed for EVD patients in Sierra Leone-China Friendship Hospital. Confirmed EVD patients were sequentially enrolled and treated with either WHO recommended supportive therapy (control group) from October 10th to 30th, or treated with WHO recommended therapy plus Favipiravir (T-705) from November 1st to 10th, 2014. Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group.

Results. The overall survival rate in the T-705 treatment group was higher than that of control group (56.4%, 22/39 vs 35.3%, 30/85, P=0.027). Among the 35 patients who finished all designed endpoint observations, the survival rate in T-705 treatment group (64.8%, 11/17) was higher than that of control group (27.8%, 5/18). Furthermore, the average survival time of the treatment group (46.9±5.6 days) was longer than that of the control group (28.9±4.7 days). Most symptoms of patients in the treatment group improved significantly. Additionally, 52.9% of patients who received T-705 had over a 100 fold viral load reduction, compared to only 16.7% of patients in the control group.

Conclusion. Treatment of EVD with T-705 was associated with prolonged survival and markedly reduced viral load, which makes a compelling case for further randomized controlled trials of T-705 for treating EVD.


Published on behalf of

cid cover HIV Medicine Association Logo

Society Members: For your free access to this journal, log in via the IDSA members area.

Impact Factor: 8.886

5-Yr impact factor: 9.206

For Reviewers

Looking for your next opportunity?

Looking for jobs...

For the Media

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.